Christopher Calcagni
Foot & Ankle Surgery · Naples, FLNPI 1285863985
Payments from drug & device makers
Across 80 payments — averaging $69.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$3K
- Arthrosurface Incorporated$608
- Organogenesis Inc.$552
- Smith+Nephew$181
- Kerecis Limited$107
- GRT US Holding, Inc.$91
- plus $622 from 16 others
What the payments were for
- Consulting fees$2004%
- Speaking & faculty fees$2004%
- Travel & lodging$4218%
- Food & beverage$1,92735%
- Education$2,77850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 12 | $3,364 |
| Arthrosurface Incorporated | 5 | $608 |
| Organogenesis Inc. | 20 | $552 |
| Smith+Nephew | 8 | $181 |
| Kerecis Limited | 2 | $107 |
| GRT US Holding, Inc. | 6 | $91 |
| Medtronic(2 entities) | 2 | $89 |
| Treace Medical Concepts, Inc. | 4 | $83 |
| Nevro Corp. | 3 | $70 |
| Stryker | 2 | $55 |
| Paratek Pharmaceuticals, Inc. | 3 | $54 |
| Flower Orthopedics Coporation | 1 | $46 |
| Amgen | 2 | $40 |
| AbbVie | 2 | $33 |
| Averitas Pharma Inc. | 1 | $31 |
| Johnson & Johnson | 1 | $24 |
| Bioventus LLC | 1 | $22 |
| DJO, LLC | 1 | $17 |
| Cardiovascular Systems Inc. | 1 | $16 |
| KCI USA, Inc. | 1 | $15 |
| Reprise Biomedical, Inc. | 1 | $13 |
| Omeza LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,526 in reported general payments places this provider in the 60th percentile of 850 foot & ankle surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 137 | $723 |
| Gentamicin Sulfate | 35 | $640 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $110 |
| Ciprofloxacin Hcl | 15 | $68 |
| Cephalexin | 14 | $50 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $34 |
| Meloxicam | 16 | $11 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Naples
- Cody TogherNaples$60K
- Richard DeaslaNaples$47K
- Thomas SangiovanniCoral Gables$2.1M
- Shayne JensenPanama City$1.3M
- Thomas RoukisOrlando$1.1M
- Craig BreslauerStuart$971K
- Bradley LammWest Palm Beach$938K
- Amber ShaneOrlando$830K
- Jonathan BlumKissimmee$814K
- Riquel GonzalezHialeah$612K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.